Cationized gelatin-HVJ envelope with sodium borocaptate improved the BNCT efficacy for liver tumors in vivo
详细信息 查看全文
- 作者：Hitoshi Fujii (1)
Akifumi Matsuyama (2)
Hiroshi Komoda (1)
Masao Sasai (2)
Minoru Suzuki (3)
Tomoyuki Asano (4)
Yuichiro Doki (1)
Mitsunori Kirihata (4)
Koji Ono (3)
Yasuhiko Tabata (5)
Yasufumi Kaneda (6)
Yoshiki Sawa (1)
Chun Man Lee (1) (2) (7) - 刊名：Radiation Oncology
- 出版年：2011
- 出版时间：December 2011
- 年：2011
- 卷：6
- 期：1
- 全文大小：1689KB
- 参考文献：1. Barth RF, Coderre JA, Vicente MG, Blue TE: Boron neutron capture therapy of cancer: current status and future prospects. / Clin Cancer Res 2005, 11:3987鈥?002. CrossRef
2. Yamamoto T, Nakai K, Matsumura A: Boron neutron capture therapy for glioblastoma. / Cancer Lett 2008, 262:143鈥?2. CrossRef
3. Pinelli T, Zonta A: / From the first idea to the application to the human liver. Research and development in Neutron Capture Therapy; 2002.
4. Suzuki M, Sakurai Y, Hagiwara S, Masunaga S, Kinashi Y, Nagata K, Maruhashi A, Kudo M, Ono K: First attempt of boron neutron capture therapy (BNCT) for hepatocellular carcinoma. / Jpn J Clin Oncol 2007, 37:376鈥?1. CrossRef
5. Wittig A, Malago M, Collette L, Huiskamp R, Buhrmann S, Nievaart V, Kaiser G, Jockel KH, Sauerwein W: BNCT in liver metastases: results of the EORTC trial 11001. / Strahlentherapie Und Onkologie 2007, 183:115鈥?15.
6. Sauerwein W, Malago M, Moss R, Altieri S, Hampel G, Wittig A, Nievaart V, Collette L, Mauri P, Huiskamp R, Michel J, Daquino G, Gerken G, Bornfeld N, Broelsch CE: Boron Neutron Capture Therapy (BNCT) for the treatment of diffuse, non-resectable liver metastases. / Strahlentherapie Und Onkologie 2006, 182:109鈥?09.
7. Cardose JE, Trivillin VA, Heber EM, Nigg DW, Calzetta O, Blaumann H, Longhino J, Itoiz ME, Bumaschny E, Pozzi E, Schwint AE: Effect of Boron Neutron Capture Therapy (BNCT) on normal liver regeneration: Towards a novel therapy for liver metastases. / International Journal of Radiation Biology 2007, 83:699鈥?06. CrossRef
8. Chou FI, Chung HP, Liu HM, Chi CW, Lui WY: Suitability of boron carriers for BNCT: Accumulation of boron in malignant and normal liver cells after treatment with BPA, BSH and BA. / Applied Radiation and Isotopes 2009, 67:S105鈥?08. CrossRef
9. Wittig A, Malago M, Collette L, Huiskamp R, Buhrmann S, Nievaart V, Kaiser GM, Jockel KH, Schmid KW, Ortmann U, Sauerwein WA: Uptake of two 10 B-compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001). / Int J Cancer 2008, 122:1164鈥?1. CrossRef
10. Suzuki M, Masunaga SI, Kinashi Y, Takagaki M, Sakurai Y, Kobayashi T, Ono K: The effects of boron neutron capture therapy on liver tumors and normal hepatocytes in mice. / Jpn J Cancer Res 2000, 91:1058鈥?4.
11. Sakurai Y, Ono K, Miyatake S, Maruhashi A: Improvement effect on the depth-dose distribution by CSF drainage and air infusion of a tumour-removed cavity in boron neutron capture therapy for malignant brain tumours. / Phys Med Biol 2006, 51:1173鈥?3. CrossRef
12. Wu G, Barth RF, Yang W, Lee RJ, Tjarks W, Backer MV, Backer JM: Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy. / Anticancer Agents Med Chem 2006, 6:167鈥?4. CrossRef
13. Mehta SC, Lu DR: Targeted drug delivery for boron neutron capture therapy. / Pharm Res 1996, 13:344鈥?1. CrossRef
14. Maruyama K, Ishida O, Kasaoka S, Takizawa T, Utoguchi N, Shinohara A, Chiba M, Kibayashi H, Eriguchi M, Yanagie H: Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT). / J Control Release 2004, 98:195鈥?07. CrossRef
15. Masunaga S, Kasaoka S, Maruyama K, NIgg D, Sakurai Y, Nagata K, Suzuki M, Kinashi Y, Maruhashi A, Ono K: The potential of transferrin-pendant-type polyethyleneglycol liposomes encapsulating decahydrodecaborate- (10) B (GB-10) as (10) B-carriers for boron neutron capture therapy. / Int J Radiat Oncol Biol Phys 2006, 66:1515鈥?2. CrossRef
16. Doi A, Kawabata S, Iida K, Yokoyama K, Kajimoto Y, Kuroiwa T, Shirakawa T, Kirihata M, Kasaoka S, Maruyama K, Kumada H, Sakurai Y, Masunaga S, Ono K, Miyatake S: Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. / J Neurooncol 2008, 87:287鈥?4. CrossRef
17. Aljabiri MR, Lodato F, Burroughs AK: Surveillance and diagnosis for hepatocellular carcinoma. / Liver Transpl 2007,13(11 Suppl 2):S2鈥?2. CrossRef
18. World Health Organization: World Health Statistics 2008/Future trends in global mortality. [http://www.who.int/whosis/whostat/2008/en/index.html]
19. Arciero CA, Sigurdson ER: Diagnosis and treatment of metastatic disease to the liver. / Semin Oncol 2008, 35:147鈥?9. CrossRef
20. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, Nakamura H, Morishita R, Kotani H: Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. / Mol Ther 2002, 6:219鈥?6. CrossRef
21. Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, Kaneda Y: Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. / Mol Cancer Ther 2006, 5:1021鈥?. CrossRef
22. Kawano H, Komaba S, Kanamori T, Kaneda Y: A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy. / BMC Med 2007, 5:1鈥?. CrossRef
23. Kurooka M, Kaneda Y: Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. / Cancer Res 2007, 67:227鈥?6. CrossRef
24. Fujihara A, Kurooka M, Miki T, Kaneda Y: Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. / Cancer Immunol Immunother 2008, 57:73鈥?4. CrossRef
25. Mima H, Tomoshige R, Kanamori T, Tabata Y, Yamamoto S, Ito S, Tamai K, Kaneda Y: Biocompatible polymer enhances the in vitro and in vivo transfection efficiency of HVJ envelope vector. / J Gene Med 2005, 7:888鈥?7. CrossRef
26. Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S, Yoshikawa H: Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. / Int J Cancer 1998, 76:418鈥?22. CrossRef
27. Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W, Kitagawa T, Ito T, Matsuda H, Miyasaka M: Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. / Cancer Res 2002, 62:4282鈥?.
28. Fukunaka Y, Iwanaga K, Morimoto K, Kakemi M, Tabata Y: Controlled release of plasmid DNA from cationized gelatin hydrogels based on hydrogel degradation. / J Control Release 2002, 80:333鈥?3. CrossRef
29. Hosseinkhani H, Aoyama T, Ogawa O, Tabata Y: Ultrasound enhancement of in vitro transfection of plasmid DNA by a cationized gelatin. / J Drug Target 2002, 10:193鈥?04. CrossRef
30. Nagata I, Kimura Y, Ito Y, Tanaka T: Temperature-Sensitive Phenomenon of Viral Maturation Observed in BHK Cells Persistently Infected with HVJ. / Virology 1972, 49:453鈥?61. CrossRef
31. Guttenberger M: Protein Determination. In / Cell Biology. A Laboratory Handbook; 295鈥?03.
32. Ogura K, Yanagie H, Eriguchi M, Lehmann EH, Kuhne G, Bayon G, Kobayashi H: Neutron capture autoradiographic study of the biodistribution of 10 B in tumor-bearing mice. / Appl Radiat Isot 2004, 61:585鈥?0. CrossRef
33. Saga K, Tamai K, Kawachi M, Shimbo T, Fujita H, Yamazaki T, Kaneda Y: Functional modification of Sendai virus by siRNA. / J Biotechnol 2008, 133:386鈥?4. CrossRef
34. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. / J Control Release 2000, 65:271鈥?4. CrossRef
35. Siwak DR, Tari AM, Lopez-Berestein G: The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. / Clin Cancer Res 2002, 8:1172鈥?181. Clin Cancer Res 2002;8:955鈥?
36. Yanagie H: / Selective Enhancement of Boron Accumulation with Boron-Entrapped Water-in-oil-in-water Emulsion in VX-2 Rabbit Hepatic Cancer Model for BNCT. Proc of 12th International Congress of Neutron Capture Therapy; 2006.
37. Ye SJ: Monte Carlo based protocol for cell survival and tumour control probability in BNCT. / Phys Med Biol 1999, 44:447鈥?1. CrossRef
38. Kobayashi T, Kanda K: Analytical calculation of boron- 10 dosage in cell nucleus for neutron capture therapy. / Radiat Res 1982, 91:77鈥?4. CrossRef
39. Kinashi Y, Masunaga S, Nagata K, Suzuki M, S T, Ono K: A bystander effect observed in boron neutron capture therapy: A study of the induction of mutations in the HPRT locus. / Int J Radiat Oncol Biol Phys 2007, 68:508鈥?4. CrossRef
40. Suzuki M, Sakurai Y, Masunaga S, Kinashi Y, Nagata K, Ono K: Dosimetric study of boron neutron capture therapy with borocaptate sodium (BSH)/lipiodol emulsion (BSH/lipiodol-BNCT) for treatment of multiple liver tumors. / Int J Radiat Oncol Biol Phys 2004, 58:892鈥?. CrossRef
41. Suzuki M, Nagata K, Masunaga S, Kinashi Y, Sakurai Y, Maruhashi A, Ono K: Biodistribution of 10 B in a rat liver tumor model following intra-arterial administration of sodium borocaptate (BSH)/degradable starch microspheres (DSM) emulsion. / Appl Radiat Isot 2004, 61:933鈥?. CrossRef
42. Yanagie H, Tomita T, Kobayashi H, Fujii Y, Nonaka Y, Saegusa Y, Hasumi K, Eriguchi M, Kobayashi T, Ono K: Inhibition of human pancreatic cancer growth in nude mice by boron neutron capture therapy. / Br J Cancer 1997, 75:660鈥?. CrossRef
43. Yanagie H, Sakurai Y, Ogura K, Kobayashi T, Furuya Y, Sugiyama H, Kobayashi H, Ono K, Nakagawa K, Takahashi H, Nakazawa M, Eriguchi M: Evaluation of neutron dosimetry on pancreatic cancer phantom model for application of intraoperative boron neutron-capture therapy. / Biomed Pharmacother 2007, 61:505鈥?4. CrossRef
44. Suzuki M, Sakurai Y, Masunaga S, Kinashi Y, Nagata K, Maruhashi A, Ono K: A preliminary experimental study of boron neutron capture therapy for malignant tumors spreading in thoracic cavity. / Jpn J Clin Oncol 2007, 37:245鈥?. CrossRef
45. Kawano H, Komaba S, Yamasaki T, Maeda M, Kimura Y, Maeda A, Kaneda Y: New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin. / Cancer Chemother Pharmacol 2008, 61:973鈥?. CrossRef - 作者单位：Hitoshi Fujii (1)
Akifumi Matsuyama (2)
Hiroshi Komoda (1)
Masao Sasai (2)
Minoru Suzuki (3)
Tomoyuki Asano (4)
Yuichiro Doki (1)
Mitsunori Kirihata (4)
Koji Ono (3)
Yasuhiko Tabata (5)
Yasufumi Kaneda (6)
Yoshiki Sawa (1)
Chun Man Lee (1) (2) (7)
1. Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
2. Medical Center for Translational Research, Osaka University Hospital, Osaka, Japan
3. Particle Radiation Oncology Research Center Laboratory, Research Reactor Institute, Kyoto University, Osaka, Japan
4. Department of Agriculture, Osaka Prefectural University, Osaka, Japan
5. Department of Biomaterials, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan
6. Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Osaka, Japan
7. Health Care Economics and Industrial Policy, Osaka University Graduate School of Medicine, Osaka, Japan
文摘
Background Boron neutron capture therapy (BNCT) is a cell-selective radiation therapy that uses the alpha particles and lithium nuclei produced by the boron neutron capture reaction. BNCT is a relatively safe tool for treating multiple or diffuse malignant tumors with little injury to normal tissue. The success or failure of BNCT depends upon the 10B compound accumulation within tumor cells and the proximity of the tumor cells to the body surface. To extend the therapeutic use of BNCT from surface tumors to visceral tumors will require 10B compounds that accumulate strongly in tumor cells without significant accumulation in normal cells, and an appropriate delivery method for deeper tissues. Hemagglutinating Virus of Japan Envelope (HVJ-E) is used as a vehicle for gene delivery because of its high ability to fuse with cells. However, its strong hemagglutination activity makes HVJ-E unsuitable for systemic administration. In this study, we developed a novel vector for 10B (sodium borocaptate: BSH) delivery using HVJ-E and cationized gelatin for treating multiple liver tumors with BNCT without severe adverse events. Methods We developed cationized gelatin conjugate HVJ-E combined with BSH (CG-HVJ-E-BSH), and evaluated its characteristics (toxicity, affinity for tumor cells, accumulation and retention in tumor cells, boron-carrying capacity to multiple liver tumors in vivo, and bio-distribution) and effectiveness in BNCT therapy in a murine model of multiple liver tumors. Results CG-HVJ-E reduced hemagglutination activity by half and was significantly less toxic in mice than HVJ-E. Higher 10B concentrations in murine osteosarcoma cells (LM8G5) were achieved with CG-HVJ-E-BSH than with BSH. When administered into mice bearing multiple LM8G5 liver tumors, the tumor/normal liver ratios of CG-HVJ-E-BSH were significantly higher than those of BSH for the first 48 hours (p < 0.05). In suppressing the spread of tumor cells in mice, BNCT treatment was as effective with CG-HVJ-E-BSH as with BSH containing a 35-fold higher 10B dose. Furthermore, CG-HVJ-E-BSH significantly increased the survival time of tumor-bearing mice compared to BSH at a comparable dosage of 10B. Conclusion CG-HVJ-E-BSH is a promising strategy for the BNCT treatment of visceral tumors without severe adverse events to surrounding normal tissues.